CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.96: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.64BCNY991.06M · vs all stocks (USD)
Revenue (TTM)
1.05BCNY156.90M · vs all stocks (USD)
Profit Margin
-35.47%Beta
0.4720xvs all stocks
52-Week Change
-11.78%vs all stocks
Market Capitalization
6.64BCNY991.06M · vs all stocks (USD)
Enterprise Value
6.33BCNY944.11M · vs all stocks (USD)
Forward P/E
4.13xPrice to Sales (TTM)
6.32xPrice to Book (MRQ)
1.65xEnterprise to Revenue
6.02xEnterprise to EBITDA
49.32xGross Margin
33.63%Profit Margin
-35.47%Operating Margin
8.95%Return on Assets (TTM)
-0.42%Return on Equity (TTM)
-9.42%Revenue (TTM)
1.05BCNY156.90M · vs all stocks (USD)
Revenue per Share (TTM)
0.5110CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-2.50%Gross Profit (TTM)
250.67MCNY37.40M · vs all stocks (USD)
EBITDA (TTM)
181.60MCNY27.10M · vs all stocks (USD)
Net Income (TTM)
-372.98MCNY-55.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
229.30%Operating Cash Flow (TTM)
57.79MCNY8.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-128.48MCNY-19.17M · vs all stocks (USD)
5-Year Average Dividend Yield
0.42%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-60.24MCNYFY2025 · Dec 31, 2025Revenue
1.17BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
857.49MCNYFY2025 · Dec 31, 2025Gross Profit
308.27MCNYFY2025 · Dec 31, 2025Operating Income
15.71MCNY2.34M · vs all stocks (USD)
Pre-tax Income
-367.82MCNYFY2025 · Dec 31, 2025Income Tax Expense
31.50MCNYFY2025 · Dec 31, 2025Net Income
-399.31MCNYFY2025 · Dec 31, 2025EBIT
-359.46MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
181.60MCNYFY2025 · Dec 31, 2025Research & Development
45.07MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
82.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.00MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.36MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1841CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1841CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.06BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.06BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-399.31MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
19.49MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-313.39MCNYFY2025 · Dec 31, 2025Free Cash Flow
-475.64MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
584.22MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-399.31MCNYFY2025 · Dec 31, 2025Other Non-cash Items
11.83MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
71.60MCNYFY2025 · Dec 31, 2025Capital Expenditures
-162.24MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.08BCNYFY2025 · Dec 31, 2025Sale of Investments
1.11BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-128.47MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
671.34MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-597.70MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-11.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
-94.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-31.54MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.06BSharesUpdated Sep 20, 2026Float Shares
1.02BSharesUpdated Sep 20, 2026% Held by Insiders
51.95%vs all stocks
% Held by Institutions
0.81%vs all stocks
Total Cash (MRQ)
904.31MCNY134.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4380CNYUpdated Sep 20, 2026Total Debt (MRQ)
720.85MCNY107.56M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1824xCurrent Ratio (MRQ)
2.08xBook Value per Share (MRQ)
1.95CNYUpdated Sep 20, 2026Total Assets
4.86BCNY725.36M · vs all stocks (USD)
Total Current Assets
1.79BCNYFY2025 · Dec 31, 2025Total Liabilities
886.97MCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.07BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
84.24MCNYFY2025 · Dec 31, 2025Total Current Liabilities
802.73MCNYFY2025 · Dec 31, 2025Cash
584.15MCNYFY2025 · Dec 31, 2025Cash Equivalents
313.25MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
897.40MCNYFY2025 · Dec 31, 2025Other Short-term Investments
90.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
120.99MCNYFY2025 · Dec 31, 2025Inventory
512.00MCNYFY2025 · Dec 31, 2025Accounts Payable
121.07MCNYFY2025 · Dec 31, 2025Short-term Debt
560.17MCNYFY2025 · Dec 31, 2025Other Current Liabilities
17.39MCNYFY2025 · Dec 31, 2025Long-term Debt
27.86MCNYFY2025 · Dec 31, 2025Common Stock (Book)
2.06BCNYFY2025 · Dec 31, 2025Retained Earnings
786.27MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.97BCNY593.01M · vs all stocks (USD)
52-Week Low
2.78CNYUpdated Sep 20, 202652-Week High
5.11CNYUpdated Sep 20, 202652-Week Change
-11.78%vs all stocks
Beta
0.4720xvs all stocks
50-Day MA
3.20CNYUpdated Sep 20, 2026200-Day MA
3.69CNYUpdated Sep 20, 2026Avg 10-Day Volume
25.17MSharesUpdated Sep 20, 2026Avg 30-Day Volume
33.22MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.1800CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.96: safe zoneNotable
Altman Z-Score: 4.96
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow